Bayhill Therapeutics Names Paul Westberg Vice President of Business Development.PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif. -- Bayhill Therapeutics Inc., a clinical-stage biotechnology company developing innovative therapies for autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause , has named Paul Westberg to the newly created position of Vice President of Business Development. Mr. Westberg will be responsible for developing strategic partnerships for some of Bayhill's key therapeutic programs. Mr. Westberg comes to Bayhill from Novacea Inc., where he was Vice President of Business Development. At Novacea, Mr. Westberg created and led the company's business and corporate development efforts surrounding its in-licensing business model. He closed two significant product licensing deals in three years, expanding and diversifying Novacea's oncology pipeline. Mr. Westberg was instrumental in raising substantial private equity funding Equity funding An investment consisting of a life insurance policy and a mutual fund. The insurance policy is paid by the collateral value of fund shares, giving the investor the advantages of insurance protection with the growth potential of a mutual fund. for Novacea and in successfully completing its initial public offering. Prior to joining Novacea, Mr. Westberg directed business development efforts at Deltagen Inc. and Collabra Pharma. He also served in finance roles at Genentech Inc. and Aviron Inc. At Genentech, Mr. Westberg led a corporate-wide working group responsible for producing a long range plan used to more effectively manage Genentech's development pipeline, commercial products, and corporate initiatives. He also provided financial and analytical support for in-licensing and co-development opportunities at the firm. Mr. Westberg earned a Master's degree master's degree n. An academic degree conferred by a college or university upon those who complete at least one year of prescribed study beyond the bachelor's degree. Noun 1. in Business Administration from the University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal , and a Bachelor of Arts degree in Applied Mathematics from the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. . "We are pleased to have Paul join our senior management team at a time when Bayhill is rapidly advancing multiple programs through the clinic," said Dr. Mark Schwartz, Chief Executive Officer. "Paul's track record of successfully completing significant deals will prove instrumental as Bayhill's partnering efforts gather momentum and become a critical company focus." "I am excited to be joining Bayhill at such an important period of the company's growth and development," said Mr. Westberg. "Bayhill has a strong management team, excellent science and a rapidly developing pipeline that may change the way the autoimmune diseases are treated, and I am pleased to be a part of such a promising firm." About Bayhill Therapeutics Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without effecting normal protective immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. cells. BHT-DNA is being studied in a Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic is an oligonucleotide Oligonucleotide A deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequence composed of two or more covalently linked nucleotides. Oligonucleotides are classified as deoxyribooligonucleotides or ribooligonucleotides. in preclinical development for systemic lupus erythematosus Systemic Lupus Erythematosus Definition Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. . More information about Bayhill Therapeutics is available at www.bayhilltherapeutics.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion